Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
US12016904B2 · kind B2 · utility
1Cited by
15References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 6, 2022 |
| Grant date | Jun 25, 2024 |
| Priority date | — |
| Expiry date | Dec 6, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P7/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.